JRCT ID: jRCTs041220021
Registered date:25/05/2022
Clinical Trial for Prevention of Cisplatin-Induced Renal Nephrotoxicity
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Cancer |
Date of first enrollment | 25/05/2022 |
Target sample size | 21 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | flopropione dosing |
Outcome(s)
Primary Outcome | Occurrence of adverse events |
---|---|
Secondary Outcome | Changes in cisplatin-induced nephrotoxicity markers |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | - Has provided written consent for participation - Age 20 or greater at the time of consent - Has never received cisplatin-containing chemotherapy - Scheduled for chemotherapy with cisplatin only or cisplatin plus other anticancer agents under hospitalization - Lung, head and neck, and other cancer patients scheduled for cisplatin regimens with doses of 80 mg/m2 or higher in patients with |
Exclude criteria | - Presence of renal dysfunction: eGFR<60 mL/min/1.73 m2 - Pregnant or possibly pregnant women - Lactating women - With a history of hypersensitivity to flopropione - Deemed ineligible for the study as determined by the principal investigator or a co-investigator |
Related Information
Primary Sponsor | Kondo Masashi |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Takenao Koseki |
Address | 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi Aichi Japan 470-1192 |
Telephone | +81-562-93-9407 |
tkoseki@fujita-hu.ac.jp | |
Affiliation | Fujita Health University |
Scientific contact | |
Name | Masashi Kondo |
Address | 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi Aichi Japan 470-1192 |
Telephone | +81-562-93-9409 |
mkond@fujita-hu.ac.jp | |
Affiliation | Fujita Health University Hospital |